ArticlePulmonary circulation2017
Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation.
Article in Pulmonary circulation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy.Advances in therapy · 2026Article
- Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute.Pulmonary circulation · 2025Article
- Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review.ClinicoEconomics and outcomes research : CEOR · 2024Review
- Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil.Pulmonary circulation · 2023Article
- Management of nontuberculous mycobacteria in lung transplant cases: an international Delphi study.ERJ open research · 2023Article
- Article
- Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.Pulmonary circulation · 2022Article
- Management of repository corticotropin injection therapy for non-infectious uveitis: a Delphi study.Acta ophthalmologica · 2021Article
- Management of Pulmonary Arterial Hypertension.Current cardiovascular risk reports · 2021Review
- Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study.BMC pulmonary medicine · 2020Article
- Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update.Current cardiology reports · 2019Review
- EXPRESS: Long term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics.Pulmonary circulation · 2019Article
- Combination Therapy in Pulmonary Arterial Hypertension: Gleaning a Practical Approach from the Randomized Trials.The International journal of angiology : official publication of the International College of Angiology, Inc · 2019Article
- What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?Current hypertension reports · 2017Review
- Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis.Pulmonary circulationArticle
- Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension.Pulmonary circulationArticle
- Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience.Therapeutic advances in respiratory diseaseArticle
- Dosing characteristics of oral treprostinil in real-world clinical practice.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral treprostinil was recently labeled for treatment of pulmonary arterial hypertension. Similar to the period immediately after parenteral treprostinil was approved, there is a significant knowledge gap for practicing physicians who might prescribe oral treprostinil. Despite its oral route of delivery, use of the drug is challenging because of the requirement for careful titration and management of drug-related adverse effects. We aimed to create a consensus document combining available evidence with expert opinion to provide guidance for use of oral treprostinil. Following a methodology commonly used in business and social sciences (the 'Delphi Process'), two investigators from the oral treprostinil (Freedom) studies created a series of statements based on available evidence and the package insert. The set of 'best practice' statements was circulated to nine other Freedom trial investigators. Their comments were incorporated into the document as new line items for further vote and comment. The subsequent document was put to vote line by line (scale of -5 to +5) and a final statement was drafted. Consensus recommendations include initial therapy with 0.125 mg for treatment naÿ patients, three times daily dosing, aggressive use of antidiarrheal medication, and a strong preference for use of the drug in combination with other approved PAH therapies. This process was particularly valuable in providing guidance for the management of adverse events (where essentially no data is available). The Delphi process was useful to codify investigator experience and subsequently develop investigator consensus about practical issues for physicians who may wish to prescribe oral treprostinil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.